Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Three-arm Clinical Trial for Patients with Hematologic Malignancies and Mismatched Donors - Haploidentical, 1 Antigen Mismatch Related or Unrelated, and Matched unrelated donor (MUD)- Using a T-cell Replete Allograft and High-dose Post-transplant Cyclophosphamide.

Next Previous
Trial Profile

Three-arm Clinical Trial for Patients with Hematologic Malignancies and Mismatched Donors - Haploidentical, 1 Antigen Mismatch Related or Unrelated, and Matched unrelated donor (MUD)- Using a T-cell Replete Allograft and High-dose Post-transplant Cyclophosphamide.

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cyclophosphamide; Fludarabine; Melphalan; Mycophenolate mofetil; Rituximab; Tacrolimus; Thiotepa
  • Indications Acute myeloid leukaemia; Aplastic anaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Graft-versus-host disease; Hodgkin's disease; Leukaemia; Lymphoma; Multiple myeloma; Myelodysplastic syndromes; Myelofibrosis; Myeloproliferative disorders; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Therapeutic Use

Most Recent Events

  • 25 Mar 2020 Biomarkers information updated
  • 16 Jul 2013 Planned number of patients changed from 213 to 237 as reported by ClinicalTrials.gov.
  • 16 Jul 2013 Planned End Date changed from 1 Nov 2014 to 1 Nov 2015 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top